Cancer-Testis Antigen GAGE-1 Expression and Serum Immunoreactivity in Hepatocellular Carcinoma
Cancer-Testis Antigen GAGE-1 Expression and Serum Immunoreactivity in Hepatocellular Carcinoma
复制标题
肝细胞癌中癌睾丸抗原 GAGE-1 的表达和血清免疫反应性
DOI：
10.4103/njcp.njcp_73_18
复制
发表时间：
2018-10-01
影响因子：
0.9
通讯作者：
Zhao, F. L.
中科院分区：
文献类型：
--
作者：
Chao, N. X.;Li, L. Z.;Zhao, F. L.
目的：为探讨癌-睾丸抗原G抗原1（GAGE-1）在肝细胞癌（HCC）诊断和靶向治疗中的应用，检测了肝癌组织中GAGE-1蛋白的表达水平及其血清免疫反应性。材料和方法：采用免疫组化方法检测肝癌组织中GAGE-1蛋白的表达。然后，我们分析了GAGE-1在HCC中的表达与临床病理参数的关系。我们通过酶联免疫吸附测定法在HCC患者血清、肝硬化患者（LC）、B型肝炎患者（HB）和正常人个体（NHS）中观察到阳性抗GAGE-1抗体反应性。结果如下：免疫组化结果显示，GAGE-1蛋白在癌组织和癌旁组织中的阳性表达率分别为43.3%（26/60）和5%（3/60）。GAGE-1蛋白在肝癌组织中的表达水平显著高于癌旁组织（P < 0.05）。GAGE-1蛋白阳性表达与临床病理参数无关（P > 0.05）。HCC、LC、HB和NHS患者血清抗GAGE-1抗体阳性率分别为23.33%（14/59）、13.1%（8/61）、3.3%（2/60）和3.4%（2/59）。抗GAGE-1抗体阳性率在肝癌组和肝硬化组明显高于乙肝组和非乙肝组（P < 0.01），但在肝癌组和肝硬化组之间（P = 0.485）、乙肝组和非乙肝组之间（P = 0.410）均无显著性差异。抗GAGE-1抗体阳性与临床病理参数无相关性（P > 0.05）。结论：这些数据说明GAGE-1蛋白表现出适度的癌症限制性表达模式和免疫原性，为GAGE-1在免疫治疗和HCC诊断中的应用奠定了基础。
Aim: To explore the use of cancer-testis antigen G antigen 1 (GAGE-1) in the diagnosis and potential therapeutic targeting of hepatocellular carcinoma (HCC), we measured the expression of GAGE-1 protein levels in HCC tissues and its serum immunoreactivity in HCC patients. Materials and Methods: We detected the expression of GAGE-1 protein in HCC by immunohistochemistry (IHC). We then analyzed the clinical significance of GAGE-1 expression in HCC with respect to clinicopathological parameters. We observed positive anti-GAGE-1 antibody reactivity in HCC patient serum, liver cirrhosis patients (LC), hepatitis B patients (HB), and normal human individuals (NHS) by enzyme-linked immunosorbent assay. Results: The IHC results showed that the positive rates of GAGE-1 protein expression in cancer tissues and adjacent tissues were 43.3% (26/60) and 5% (3/60), respectively. The expression level of GAGE-1 protein in HCC tissues was significantly higher than that in tumor-adjacent tissues (P < 0.05). Positive GAGE-1 protein expression was not correlated with clinicopathological parameters (P > 0.05). Positive serum anti-GAGE-1 antibody reactivity in HCC patients, LC, HB, and NHS was 23.33% (14/59), 13.1% (8/61), 3.3% (2/60), and 3.4% (2/59), respectively. The frequency of anti-GAGE-1 antibody-positive sera in HCC patients and LC was significantly different than that in HB and NHS (P < 0.01), but no significant differences were found between HCC patients and LC (P = 0.485) or between HB and NHS (P = 0.410). Positive anti-GAGE-1 antibody reactivity was not correlated with clinicopathological parameters (P > 0.05). Conclusion: These data illustrate that the GAGE-1 protein exhibits moderate cancer-restricted pattern of expression and immunogenicity, laying the foundation for the application of GAGE-1 in immunotherapy and for the diagnosis of HCC.